Table S1 (Supplemental Data)

Between-Group Differences in Baseline Demographic, Clinical, and Medication Characteristics

Among Patients Treated with Cognitive Enhancement Therapy or Enriched Supportive Therapy.

	CET (N = 31)		ES	EST	
			(N = 27)		
Variable	M	SD	\overline{M}	SD	p^{a}
Demographics					-
Age	25.88	6.46	25.97	6.26	.955
Male $(N/\%)$	20	65%	20	74%	.617
Caucasian (N / %)	21	68%	19	70%	.662
Completed College (<i>N</i> / %)	9	29%	10	37%	.713
Employed $(N / \%)$	8	26%	7	26%	.772
Schizophrenia (N / %)	21	68%	17	63%	.916
Years Since First Psychotic Symptom	3.07	2.34	3.32	2.16	.675
IQ	97.74	7.66	98.52	9.74	.736
Symptoms					
BPRS Total	39.77	9.21	40.70	10.64	.723
Wing Negative Symptoms Scale	18.35	4.14	18.15	3.63	.842
Raskin Depression Scale	6.77	2.77	6.33	1.98	.494
Covi Anxiety Scale	5.84	2.08	6.11	2.22	.632
Treatment Exposure/Adherence ^b					
Total Hours of Treatment	162.27	43.40	45.80	17.99	< .001
% Sessions Missed	11.29	6.97	16.29	15.14	.141
Medications					
Dose (baseline, cpz)	405.38	339.95	460.68	335.05	.536
Dose (year 1, cpz)	402.33	332.93	529.38	374.13	.215
Dose (year 2, cpz)	473.58	384.43	548.71	402.05	.520
Using Atypical Agent (baseline, $N/\%$)	31	100%	26	96%	.944
Using Atypical Agent (year $1, N/\%$)	25	100%	24	100%	.886
Using Atypical Agent (year 2, $N/\%$)	24	100%	22	100%	.768
Compliant (baseline, $N/\%$)	28	90%	24	89%	.800
Compliant (year $1, N/\%$)	25	100%	20	83%	.108
Compliant (year $2, N/\%$)	22	92%	19	86%	.918

Note. CET = Cognitive Enhancement Therapy, BPRS = Brief Psychiatric Rating Scale, EST = Enriched Supportive Therapy.

 $^{^{}a}\chi^{2}$ test or independent *t*-test, two-tailed, for significant differences between CET and EST participants.

 $^{^{}b}N = 49$, as treatment exposure/adherence data were not collected from individuals who withdrew from treatment before one year.